ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2021
Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Diagnostic challenges in isolated cardiac sarcoidosis.ESC heart failure · 2026Review
- Emerging PET-radiotracers in cardiovascular, neuro-inflammation, lung and rheumatological diseases: a narrative review.EJNMMI reports · 2025Review
- From FDG and beyond: the evolving potential of nuclear medicine.Annals of nuclear medicine · 2023Review
- Potential clinical utility ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Detection of apoptosis by [Annals of nuclear medicine · 2023Article
- Potential novel imaging targets of inflammation in cardiac sarcoidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Review
- Detection of cardiac apoptosis by [Molecular imaging and biology · 2022Article
- Advances in Diagnostic Imaging for Cardiac Sarcoidosis.Journal of clinical medicine · 2021Review
- PET Imaging in Cardiac Sarcoidosis: A Narrative Review with Focus on Novel PET Tracers.Pharmaceuticals (Basel, Switzerland) · 2021Review
- 2020 vision: New insights on hypoxia imaging to assess cardiac and extra-cardiac active inflammatory sarcoidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- The Role of Multimodality Imaging in Cardiac Sarcoidosis.Korean circulation journal · 2021Review
- Clinical Features and Diagnosis of Cardiac Sarcoidosis.Journal of clinical medicine · 2021Review
- Hypoxia Promotes a Mixed Inflammatory-Fibrotic Macrophages Phenotype in Active Sarcoidosis.Frontiers in immunology · 2021Article
- Cardiac 18F-FDG Positron Emission Tomography: An Accurate Tool to MonitorFrontiers in cardiovascular medicine · 2021Article
- Positron emission tomography/MRI for cardiac diseases assessment.The British journal of radiology · 2020Review
Corrections and comments
- Commented on by
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
methodsTen consecutive sarcoidosis patients with suspected cardiac involvement were prospectively enrolled. Each patient fasted overnight (for ≥ 18 hours) preceded by a low-carbohydrate diet before FDG PET/CT but not given special dietary instructions before the FMISO PET/CT scan. We visually and semiquantitatively assessed the uptakes of FMISO and FDG using the maximal standardized uptake value (SUV
resultsNine patients showed focal FDG uptake in the myocardium and were diagnosed with cardiac sarcoidosis. Among the patients with extra-cardiac lesions, FDG uptake was seen in 8 lymph nodes and 3 lung lesions. FMISO uptake was seen in the 7 cardiac (77.8%) and 6 extra-cardiac (54.5%) lesions. None of the patients showed physiological FMISO uptake in the myocardium. The SUV
conclusionsFMISO showed no physiological myocardial uptake and did not require special preparation. FMISO PET has the potential to detect hypoxic lesions in patients with sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.